Supernus Pharmaceuticals, Inc. News Headlines

SUPN 
$9.78
*  
0.32
3.38%
Get SUPN Alerts
*Delayed - data as of Mar. 5, 2015 13:30 ET  -  Find a broker to begin trading SUPN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    SUPN Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Supernus: A Specialty Pharma With Significant Growth Potential
2/24/2015 8:25:00 AM - Seeking Alpha


Supernus Files Oxtellar XR Patent Infringement Lawsuit Again - Analyst Blog
1/26/2015 4:00:00 PM - Zacks.com


Supernus Files Oxtellar XR Patent Infringement Lawsuit Again - Analyst Blog
1/26/2015 4:00:00 AM - Investopedia


SUPN In Legal Bout, NSPR Put On Notice, It''s Advantage TEVA, KTWO Gets FDA Nod
1/22/2015 12:48:00 AM - RTT News


Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog
1/20/2015 5:00:00 PM - Zacks.com


Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog
1/20/2015 5:00:00 AM - Investopedia


Actavis' Appeal Case for Namenda Gets Accelerated Hearing - Analyst Blog
1/7/2015 4:35:00 PM - Zacks.com


KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog
1/7/2015 2:28:00 PM - Investopedia


KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog
1/7/2015 2:28:00 PM - Zacks.com


Actavis' Appeal Case for Namenda Gets Accelerated Hearing - Analyst Blog
1/7/2015 4:35:00 AM - Investopedia


Why Supernus Pharmaceuticals (SUPN) Might Be a Diamond in the Rough - Tale of the Tape
12/15/2014 8:54:00 AM - Zacks.com


Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
12/11/2014 3:20:00 PM - Zacks.com


Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
12/10/2014 2:50:00 PM - Zacks.com


Supernus Pharma Reports Paragraph IV ANDA Filing For Oxtellar XR - Quick Facts
12/10/2014 7:36:00 AM - RTT News


Why Supernus Pharmaceuticals (SUPN) Could Be Positioned for a Surge? - Tale of the Tape
12/2/2014 8:30:00 AM - Zacks.com


How Supernus Pharmaceuticals (SUPN) Stock Stands Out in a Strong Industry - Tale of the Tape
12/1/2014 9:01:00 AM - Zacks.com


Supernus Files Trokendi XR Patent Infringement Lawsuit - Analyst Blog
11/24/2014 6:00:00 PM - Zacks.com


Third Quarter Was Robert Bruce's Busiest in 2014
11/21/2014 5:09:44 PM - GuruFocus


Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 9.8% - Tale of the Tape
11/19/2014 9:32:00 AM - Zacks.com


After-Hours Earnings Report for November 11, 2014 : FOSL, YY, TAHO, HMIN, LXFT, STKL, AERI, MGNX, SUPN, PFIE, FATE, CLSN
11/11/2014 2:00:03 PM - NASDAQ.com News


Supernus' Trokendi XR Faces Generic Threat from Zydus - Analyst Blog
10/15/2014 5:45:00 PM - Zacks.com


Actavis in Acquisition Mode, Durata Deal to Boost Portfolio - Analyst Blog
10/7/2014 4:42:00 PM - Zacks.com


Supernus Up, Files Lawsuit against Actavis for Trokendi XR - Analyst Blog
10/6/2014 1:20:00 PM - Zacks.com


Dr. Reddy's (RDY) Generic Xopenex Launched in the US - Analyst Blog
9/25/2014 5:19:00 PM - Zacks.com


Supernus Confirms 2014 Outlook, Epilepsy Products in Focus - Analyst Blog
9/23/2014 3:55:00 PM - Zacks.com